Good Marks for Vertex's All-Oral Hep C Combo
Share
Follow Us
Analyst Blog
Positive Data on VRTX Combo Therapy
By: Zacks Equity Research
February 29, 2012
Vertex Pharmaceuticals Inc. (VRTX) recently reported positive interim data from two treatment arms (E and F) of a mid-stage study (ZENITH) of VX-222, when dosed in combination with Incivek (telaprevir) and ribavirin in treatment-naïve patients with genotype 1 (1a and 1b) hepatitis C virus (HCV).
Each arm (E and F) of the ZENITH study, which consisted of 23 patients, was conducted to determine whether a patient was eligible to stop all treatment at 12 weeks. The trial results demonstrated that eleven patients met the criteria of having undetectable HCV at weeks two and eight and were therefore eligible to stop all treatment at week 12 week.
We note that on the basis of these data, Vertex Pharma plans to commence a phase IIb study to evaluate treatment with VX-222 in combination with Incivek and ribavirin for 12 weeks in treatment-naïve patients with genotype 1 HCV.
Continue reading this entire article:
http://www.zacks.com/stock/news/70549/Positive+Data+on+VRTX+Combo+Therapy
